Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.65 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | IL1B | P01584 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31013928 | 1.00 | CRBN (0.65) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL31013981 | 1.00 | CRBN (0.65) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL845434 | 0.89 | CRBN (0.57) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL3125601 | 0.88 | CRBN (0.55) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL18263933 | 0.88 | CRBN (0.55) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL22502405 | 0.83 | CRBN (0.57) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL7346208 | 0.83 | CRBN (0.57) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL455269 | 0.79 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL7581 | 0.79 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL411178 | 0.79 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363633-A1 | SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING | UNITED STATES GOVERNMENT | 2022-11-17 | — | — | US | disclosed |
| US-8198287-B2 | Substituted heteroaryl pyridopyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| US-8148364-B2 | Substituted bicyclic pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| US-20110294786-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-1957492-B1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | disclosed |
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | US | disclosed |
| EP-2121635-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| EP-1957492-A2 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | sanofi-aventis (FR) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| EP-1790649-A1 | Substituted bicyclic pyrimidone derivatives | Sanofi-Aventis (FR) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007057790-A2 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294786-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | CRBN 1359/4885DDB1 3607/4885IKZF3 1943/4885 |
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | GSK3B, GSK3A, GSKIP | CRBN 574/4885DDB1 3665/4885IKZF3 1486/4885 |
| US-20220363633-A1 | SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING | EED, EZH2, ELP1 | CRBN 973/4885DDB1 1106/4885IKZF3 840/4885 |
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | CRBN 1359/4885DDB1 3607/4885IKZF3 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.